Due to increased demand, the Food and Drug Administration has placed Tamiflu (oseltamivir phosphate) oral suspension (6 mg/ml; 60 mL) on its current drug shortages index. The manufacturer Genentech has the product on intermittent backorder.
However, supplies remain in distribution at wholesalers and pharmacies. Tamiflu 30 mg, 45 mg, and 75 mg capsules remain available. Pharmacies attempting to manage supply and demand by dispensing partial fills, especially to a facility treating confirmed infection or post-exposure prophylaxis, should make sure patients and caretakers understand why they are receiving a partial.
If there is difficulty locating commercial Tamiflu for Oral Suspension, the FDA is reminding health care professionals of the FDA-approved instructions for the emergency compounding of an oral suspension from Tamiflu 75 mg capsules. These instructions provide for an alternative oral suspension when the commercially manufactured formulation is not readily available.
Alternatives to Tamiflu treatment for influenza are described on the Centers for Disease Control and Prevention website.
Pharmacists are encouraged to visit CDC’s dedicated page for the flu for the latest updates.
Information provided from NCPA’s eNews Weekly.